BioTelemetry, Inc. (BEAT) Holdings Maintained by DAFNA Capital Management LLC
DAFNA Capital Management LLC maintained its stake in shares of BioTelemetry, Inc. (NASDAQ:BEAT) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 75,000 shares of the medical research company’s stock at the end of the second quarter. BioTelemetry comprises approximately 1.8% of DAFNA Capital Management LLC’s investment portfolio, making the stock its 14th biggest position. DAFNA Capital Management LLC owned approximately 0.23% of BioTelemetry worth $2,509,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in BEAT. BlackRock Inc. grew its holdings in shares of BioTelemetry by 69,017.8% in the 1st quarter. BlackRock Inc. now owns 3,509,112 shares of the medical research company’s stock valued at $101,587,000 after acquiring an additional 3,504,035 shares in the last quarter. Hood River Capital Management LLC bought a new position in shares of BioTelemetry in the 2nd quarter valued at about $26,694,000. Russell Investments Group Ltd. grew its holdings in shares of BioTelemetry by 115.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 970,162 shares of the medical research company’s stock valued at $32,453,000 after acquiring an additional 519,267 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of BioTelemetry by 95.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,031,594 shares of the medical research company’s stock valued at $34,506,000 after acquiring an additional 504,869 shares in the last quarter. Finally, Hodges Capital Management Inc. bought a new position in shares of BioTelemetry in the 2nd quarter valued at about $14,720,000. Institutional investors own 77.60% of the company’s stock.
BEAT has been the subject of several analyst reports. Sidoti restated a “buy” rating and issued a $49.00 price objective (up previously from $42.00) on shares of BioTelemetry in a report on Thursday, August 10th. Dougherty & Co raised their price objective on BioTelemetry from $37.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. BidaskClub cut BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Benchmark Co. raised their price objective on BioTelemetry from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, July 19th. Finally, Lake Street Capital restated a “buy” rating and issued a $50.00 price objective (up previously from $35.00) on shares of BioTelemetry in a report on Friday, July 14th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $44.40.
Shares of BioTelemetry, Inc. (NASDAQ:BEAT) traded up 0.15% during midday trading on Thursday, reaching $34.40. 181,884 shares of the company traded hands. The firm has a market capitalization of $1.11 billion, a PE ratio of 23.09 and a beta of 0.68. BioTelemetry, Inc. has a 12-month low of $15.25 and a 12-month high of $39.20. The company has a 50-day moving average of $35.02 and a 200 day moving average of $31.93.
BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings data on Tuesday, August 8th. The medical research company reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.02. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. The business had revenue of $58.10 million during the quarter, compared to the consensus estimate of $58.39 million. During the same period in the prior year, the firm posted $0.20 EPS. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. On average, equities analysts forecast that BioTelemetry, Inc. will post $0.99 earnings per share for the current year.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.